Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Tests and Tools for Detecting Iron Overload

January 14th 2015

Risk Stratification and Recommendations to Mitigate Iron Overload

January 14th 2015

Anemia and Iron Overload: Prevalence in Patients With MDS

January 14th 2015

Final Comments From Panelists on Managing CML

January 14th 2015

Feasibility of TKI Discontinuation in CML

January 14th 2015

Addressing Fluctuating BCR-ABL Levels in CML

January 14th 2015

Utilizing Omacetaxine in Chronic Myeloid Leukemia

January 14th 2015

Ponatinib Effective in Resistant CML

January 14th 2015

Utilizing Second-Line Bosutinib in Ph+ CML

January 14th 2015

First- and Second-Line Nilotinib in CML

January 14th 2015

Dasatinib in the Second-Line CML Setting

January 14th 2015

Promises and Challenges of Ponatinib in CML

January 14th 2015

First-Line Dasatinib in Chronic Myeloid Leukemia

January 14th 2015

Treatment Selection for Newly Diagnosed Patients With CML

January 14th 2015

Importance of Monitoring Patients With CML

January 14th 2015

Optimal Timing for Follow-up Mutation Testing in CML

January 14th 2015

Introduction: Role of Genetic Testing in CML

January 14th 2015

PD-1 Pathway Blockade May Shape the Future of Hodgkin Lymphoma Therapy

January 14th 2015

Agents that target components of the programmed death-1 (PD-1) pathway are poised to make an impact on the treatment of patients with hematologic malignancies, particularly Hodgkin lymphoma (HL).

Dr. Powell on CPI-613, Cytarabine, Mitoxantrone Combo for AML

January 9th 2015

Final Thoughts on AML and ALL

January 9th 2015